A carregar...
Mechanisms of and approaches to overcoming resistance to immunotherapy
Immunotherapies have been successfully developed for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) with FDA approval of blinatumomab, inotuzumab, and tisagenlecleucel for relapsed or refractory patients. These agents target either CD19 or CD22, which are both expressed on the surface...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913466/ https://ncbi.nlm.nih.gov/pubmed/31808880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000018 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|